retatrutide nonalcoholic steatohepatitis trial fatty liver disease Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Xia & He Publishing – FDA Approves First NASH Drug

The result is a dampened metabolic signal: blood sugar rises higher after eating, stays elevated longer, and the calming, energy-stabilizing effect of natural GLP-1 weakens

Ipamorelin, acting on a separate ghrelin-receptor pathway, can amplify that release while remaining relatively selective

Did you share on the podcast

These factors make it difficult to determine if improvements were caused by the GLP-1 RA

doi: 10.1152/physrev.00034.2006 36 BeiroaDImbernonMGallegoRSenraAHerranzDVillarroyaFet al

The gradual weight reduction typically achieved with these medications has not been associated with clinically significant changes in thrombotic risk in clinical trials